NeuBase Therapeutics (STU:O7P) Total Stockholders Equity : €8.56 Mil (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics Total Stockholders Equity?

NeuBase Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2023 was €8.56 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. NeuBase Therapeutics's Book Value per Share for the quarter that ended in Sep. 2023 was €2.30. The ratio of a company's debt over equity can be used to measure how leveraged this company is. NeuBase Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2023 was 0.58.

NeuBase Therapeutics Total Stockholders Equity Historical Data

The historical data trend for NeuBase Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Total Stockholders Equity Chart

NeuBase Therapeutics Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Total Stockholders Equity

Get a 7-Day Free Trial

19.17

-0.04

9.11

26.57

45.96

NeuBase Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Stockholders Equity	Get a 7-Day Free Trial															23.42	17.20	13.49	10.38	8.56

NeuBase Therapeutics (STU:O7P) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

NeuBase Therapeutics's Book Value per Share for the quarter that ended in Sep. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(8.561	-	0)	/	3.72921
	=	2.30

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

NeuBase Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.469	+	4.529)	/	8.561
	=	0.58

NeuBase Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (STU:O7P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

NBSE:USA O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines